All of Sequent’s other existing backers took part in the financing, including Domain Associates, US Venture Partners and Versant Ventures.
The company, which was launched in 2007, develops catheter-based system for treating problems with the brain such as aneurysms.
Sequent president and CEO Tom Wilder said, “We appreciate the continued support from our investor consortium as we continue to build Sequent into a leading neurovascular franchise.
“We will use the funds to continue our introduction of the WEBTM Aneurysm Embolization System, including execution of our planned US IDE clinical study, and to broaden our product portfolio.”
Copyright © 2014 AltAssets